Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NB14

UPID:
UBP38_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 38; HP43.8KD; Ubiquitin thioesterase 38; Ubiquitin-specific-processing protease 38

ALTERNATIVE UPACC:
Q8NB14; B3KX93; Q3ZCV1; Q8NDF5; Q96DK6; Q96PZ6; Q9BY55

BACKGROUND:
Ubiquitin carboxyl-terminal hydrolase 38, with alternative names such as Ubiquitin-specific-processing protease 38, is a deubiquitinating enzyme that influences various critical cellular mechanisms, including the immune response and cell proliferation. It plays a significant role in the DNA damage response and antiviral response, showcasing its versatility in cellular regulation and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin carboxyl-terminal hydrolase 38 holds promise for identifying novel therapeutic approaches. Its critical role in cellular regulation and response to DNA damage and viral infections highlights its potential as a therapeutic target, offering opportunities for the development of innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.